Catalog No.: PC-49608Not For Human Use, Lab Use Only.
Halofuginol (MAZ1805) is a halofuginone analog targeting the Plasmodium falciparum prolyl-tRNA synthetase (PfcPRS, Ki=71.1 nM), is highly active against both liver and asexual blood stages of the malaria parasite (EC50=5.8 nM, P. falciparum 3D7 parasite strain).
Halofuginol (MAZ1805) is a halofuginone analog targeting the Plasmodium falciparum prolyl-tRNA synthetase (PfcPRS, Ki=71.1 nM), is highly active against both liver and asexual blood stages of the malaria parasite (EC50=5.8 nM, P. falciparum 3D7 parasite strain).
Halofuginol is approximately 65 times more selective for P. falciparum than primary mouse embryonic fibroblasts.
Halofuginol has similar activity (EC50=14 nM) to halofuginone (EC50 = 17 nM) in the in vitro P. berghei ANKA liver stage model.
Halofuginol (5 mg/kg, i.p. or 10 mg/kg p.o) is active against the asexual erythrocytic and liver stages of the malaria parasite in P. berghei sporozoite challenge model, reduces parasite burden by more than 95%.
